EyePoint Pharmaceuticals (NASDAQ:EYPT) Rating Increased to Sell at StockNews.com

EyePoint Pharmaceuticals (NASDAQ:EYPT) was upgraded by equities researchers at StockNews.com to a “sell” rating in a research note issued on Saturday.

A number of other research firms also recently issued reports on EYPT. Chardan Capital reissued a “buy” rating and set a $28.00 price target on shares of EyePoint Pharmaceuticals in a research report on Friday, June 28th. Cantor Fitzgerald restated an “overweight” rating on shares of EyePoint Pharmaceuticals in a research note on Thursday, June 20th. JPMorgan Chase & Co. decreased their price objective on EyePoint Pharmaceuticals from $32.00 to $29.00 and set an “overweight” rating for the company in a research note on Tuesday, August 13th. Jefferies Financial Group began coverage on EyePoint Pharmaceuticals in a research note on Wednesday, August 28th. They issued a “buy” rating and a $15.00 price target for the company. Finally, HC Wainwright reiterated a “buy” rating and issued a $30.00 price target on shares of EyePoint Pharmaceuticals in a research note on Thursday, June 27th. One equities research analyst has rated the stock with a sell rating and eight have issued a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $30.57.

EyePoint Pharmaceuticals Stock Down 2.9 %

Shares of EyePoint Pharmaceuticals stock opened at $8.91 on Friday. The stock’s fifty day moving average is $8.85 and its two-hundred day moving average is $12.73. The company has a market capitalization of $464.07 million, a PE ratio of -4.90 and a beta of 1.59. EyePoint Pharmaceuticals has a 52 week low of $5.67 and a 52 week high of $30.99.

EyePoint Pharmaceuticals (NASDAQ:EYPT) last announced its quarterly earnings data on Wednesday, August 7th. The company reported ($0.58) EPS for the quarter, missing the consensus estimate of ($0.55) by ($0.03). The business had revenue of $9.48 million during the quarter, compared to the consensus estimate of $11.61 million. EyePoint Pharmaceuticals had a negative net margin of 172.29% and a negative return on equity of 43.24%. As a group, research analysts anticipate that EyePoint Pharmaceuticals will post -2.33 earnings per share for the current year.

Insider Transactions at EyePoint Pharmaceuticals

In related news, Director David R. Guyer sold 11,625 shares of EyePoint Pharmaceuticals stock in a transaction that occurred on Friday, July 12th. The stock was sold at an average price of $10.06, for a total transaction of $116,947.50. Following the transaction, the director now owns 1,850 shares in the company, valued at $18,611. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 4.74% of the company’s stock.

Institutional Investors Weigh In On EyePoint Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in EYPT. Ghisallo Capital Management LLC acquired a new stake in shares of EyePoint Pharmaceuticals in the fourth quarter valued at $2,511,000. Healthcare of Ontario Pension Plan Trust Fund acquired a new position in shares of EyePoint Pharmaceuticals during the 4th quarter worth about $3,166,000. Ratan Capital Management LP acquired a new position in shares of EyePoint Pharmaceuticals during the 4th quarter worth about $1,040,000. Janney Montgomery Scott LLC boosted its position in shares of EyePoint Pharmaceuticals by 26.5% during the 1st quarter. Janney Montgomery Scott LLC now owns 18,040 shares of the company’s stock worth $373,000 after acquiring an additional 3,780 shares in the last quarter. Finally, American International Group Inc. boosted its position in shares of EyePoint Pharmaceuticals by 38.4% during the 1st quarter. American International Group Inc. now owns 18,378 shares of the company’s stock worth $380,000 after acquiring an additional 5,101 shares in the last quarter. Hedge funds and other institutional investors own 99.41% of the company’s stock.

EyePoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.